None listed
Conditions
Brief summary
Globally, Ischemic heart disease (IHD) is the only heart disease that has a distressing impact on human health and life. In 2010, more than 7.0 million people died from IHD all over the world and it has been estimated that IHD will become 2nd leading cause of death by 2020. There is also a large geographical inconsistency in the occurrence of IHD risk factors. So, it is important to determine the relationship between the present risk factors and IHD in developing countries as well. IHD requires long-term management and adherence to these medicines is essential while non-adherence links to subsequent cardiovascular events and mortality. Pharmacists can make necessary efforts to make safe medication use and to achieve the desired outcomes through educating the patients about the medication and managing the diseases. But there is uncertainty about the role and impact of pharmacists on the morbidity and mortality of IHD. The aim of this interventional study is to determine the disease burden and risk factors of IHD as well as the impact of Clinical pharmacists on the disease management and reduction of risk factors in patients with ischemic heart diseases in different cardiovascular settings in the city of Lahore, Pakistan. Study subjects who are diagnosed with Ischemic heart disease are attended by Cardiologists at the hospital. A convenience sampling technique will be used for recruiting the study subject. A questionnaire and face-to-face interview will be used as a study tool in this project. All eligible, consecutively enrolled ischemic patients at the study sites will be included in the study until the required number of patients is enrolled. SPSS version 23 will be used to analyze the data. Pharmacist intervention also plays an important role to reduce morbidity and mortality of ischemic heart diseases. The overall quality and safety of patients with ischemic heart diseases will be improved by finding the actual risk factors in patients and following the treatment protocol by the cardiologists and adhering to medicines by the patients.
Interventions
Step 1:
First of all, the study population (Ischemic Heart Disease Patients) will be selected from the selective cardiovascular settings and the attendance of each patient will be marked at the time of visit.
Step 2:
The Principle Investigator (Clinical Pharmacist) will check the patients profile and overview the patient disease and medicine history.
Step 3:
One-on-one face-to-face interventional counseling sessions e.g. cognitive behavioral therapy, open discussion of 30 minutes will be conduct
Step 1: First of all, the study population (Ischemic Heart Disease Patients) will be selected from the selective cardiovascular settings and the attendance of each patient will be marked at the time of visit. Step 2: The Principle Investigator (Clinical Pharmacist) will check the patients profile and overview the patient disease and medicine history. Step 3: One-on-one face-to-face interventional counseling sessions e.g. cognitive behavioral therapy, open discussion of 30 minutes will be conducted on the ischemic patients about the disease and risk management, correct use of medicine and lifestyle modification (diet and exercise) fortnightly for 6 months. Risk factors for ischemic heart disease, medication routines, and current lifestyle practices will also be discussed with the patients fortnightly. Both types of intervention (Digital Intervention and educational intervention) will be provided during interventional counseling sessions by the Clinical Pharmacist to ischemic patients at the start of the study and be advised to complete these at their own pace. Digital Intervention: The components of digital intervention include digital pictures, and short videos (3-15 minutes) to manage the disease. Online links of pictures and videos (Source: google and google scholar) will be shared weekly on their personal devices. Participants will be instructed to watch a short video outlining strategies that can be used to manage their risk factors and ischemic heart disease progression. The adherence to intervention and patient’s response will be monitored after 6 months of study via a study-specific questionnaire about whether they watched the video and what they learned from the videos. Educational intervention: The online available written material providing advice to modify lifestyle risk factors to manage disease progression will be used for educational intervention. It is expected that participants will spend a minimum of half an hour and a maximum of an hour reading through the content. Step 4: The participant’s response will be monitored via a study-specific questionnaire after 6 months of interventional session.
Sponsors
Dr. Amjad Khan
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Educational / counselling / training
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with confirmed ischemic heart diseases (e.g Myocardial infarction, angina, history of atherosclerosis) who are admitted to and taking follow-up treatment in the Punjab Institute of Cardiology (PIC) hospital will be recruited for the study. Patients with a previous history of coronary heart disease will also be included. Informed consent will be taken from the patients before conducting the study
Exclusion criteria
Cardiovascular patients other than ischemic heart diseases will be excluded from the study. Patients who have a shorter stay in the hospital, do not have to ability to self-care, cognitively impaired patients, allergic or contraindicated to cardiovascular medicines, have communicable diseases, and could not complete the study due to hepatic or renal insufficiencies and refused to include in the study would be excluded from the study.
Outcome results
None listed